OCUGEN, INC. Proceeds from Issuance of Debt
OCUGEN, INC. (OCGN) reported Proceeds from Issuance of Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2026-03-04
- OCUGEN, INC. proceeds from issuance of debt for the quarter ending 2024-12-31 was $30.00M.
- OCUGEN, INC. proceeds from issuance of debt for the quarter ending 2024-09-30 was $0.00.
- OCUGEN, INC. proceeds from issuance of debt for the quarter ending 2023-12-31 was $0.00.
- OCUGEN, INC. proceeds from issuance of debt for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- OCUGEN, INC. proceeds from issuance of debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- OCUGEN, INC. proceeds from issuance of debt for fiscal 2024 was $30.00M, a 5900.00% increase from fiscal 2023.
- OCUGEN, INC. proceeds from issuance of debt for fiscal 2023 was $500.00K, a 0.00% change from fiscal 2022.
- OCUGEN, INC. proceeds from issuance of debt for fiscal 2022 was $500.00K.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-04 | |||
| 2024-12-31 | $30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $30.00M derived: sum of 2 quarters · filed 2026-03-04 | $30.00M 10-K · filed 2026-03-04 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | $500.00K 10-K · filed 2025-03-05 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $500.00K 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $500.00K 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-K 9 month · filed 2024-04-16 | $500.00K derived: sum of 2 quarters · filed 2024-04-16 | $500.00K 10-K · filed 2024-04-16 | |
| 2022-09-30 | $500.00K derived: 10-K 9 month − 10-K 6 month · filed 2024-04-16 | $500.00K 10-K · filed 2024-04-16 | ||
| 2022-06-30 | $0.00 10-K · filed 2024-04-16 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $921.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $921.00K 10-Q · filed 2021-08-06 | |||
| 2014-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $1.75M 10-K · filed 2016-03-10 | ||
| 2014-09-30 | $464.00K 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |